{"id":"levoxyl","rwe":[],"_fda":{"id":"f059a576-bb4b-441d-917e-4338bc3df403","set_id":"008de8fd-150f-4022-8ccb-c8bfa94875c7","openfda":{"unii":["9J765S329G"],"route":["ORAL"],"rxcui":["966249"],"spl_id":["f059a576-bb4b-441d-917e-4338bc3df403"],"brand_name":["Levothyroxine sodium"],"spl_set_id":["008de8fd-150f-4022-8ccb-c8bfa94875c7"],"package_ndc":["50090-6115-0","50090-6115-1"],"product_ndc":["50090-6115"],"generic_name":["LEVOTHYROXINE SODIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["LEVOTHYROXINE SODIUM"],"manufacturer_name":["A-S Medication Solutions"],"application_number":["ANDA212399"],"original_packager_product_ndc":["16729-456"]},"version":"8","pregnancy":["8.1 Pregnancy Risk Summary The clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and levothyroxine sodium dosage adjusted during pregnancy (see Clinical Considerations) . Animal reproductive studies have not been conducted with levothyroxine sodium. Levothyroxine sodium should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre‑eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development. Dose Adjustments During Pregnancy and the Postpartum Period Pregnancy may increase levothyroxine sodium requirements. Serum TSH levels should be monitored and the levothyroxine sodium dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the levothyroxine sodium dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration (2.3) ]."],"overdosage":["10 OVERDOSAGE The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions (5) and Adverse Reactions (6) ] . In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year-old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium. Reduce the levothyroxine sodium dosage or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient’s medical status. For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org."],"description":["11 DESCRIPTION Levothyroxine sodium tablets, USP is L-thyroxine (T4) and contains synthetic crystalline L-3,3’,5,5’-tetraiodothyronine sodium salt. Synthetic T4 is chemically identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C 15 H 10 I 4 N NaO 4 • H 2 O, molecular weight of 798.86 (anhydrous), and structural formula as shown: Levothyroxine sodium tablets, USP for oral administration are supplied in the following strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Each levothyroxine sodium tablet contains the inactive ingredients microcrystalline sodium, light magnesium oxide, sodium starch glycolate and sodium stearyl fumarate. Levothyroxine sodium tablets, USP contain no ingredients made from a gluten-containing grain (wheat, barley, or rye). Table 9 provides a listing of the color additives by tablet strength: Table 9. Levothyroxine Sodium Tablet Color Additives Strength (mcg) Color additive(s) 25 FD&C Yellow No. 6 Aluminum Lake 50 None 75 FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake 88 FD&C Blue No. 2 Aluminum Lake, FD&C Yellow No. 5 Aluminum Lake 100 FD&C Yellow No. 5 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake 112 FD&C Red No. 40 Aluminum Lake, Carmine 125 FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake 137 FD&C Blue No. 1 Aluminum Lake 150 FD&C Blue No. 2 Aluminum Lake 175 FD&C Blue No. 1 Aluminum Lake, Carmine 200 FD&C Red No. 40 Aluminum Lake 300 D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake Levothyroxine sodium tablets, USP meets USP Dissolution Test 7. description"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Product: 50090-6115 NDC: 50090-6115-0 30 TABLET in a BOTTLE NDC: 50090-6115-1 90 TABLET in a BOTTLE"],"boxed_warning":["WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including levothyroxine sodium, should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity (6 , 10) ."],"geriatric_use":["8.5 Geriatric Use Because of the increased prevalence of cardiovascular disease among the elderly, initiate levothyroxine sodium at less than the full replacement dose [see Dosage and Administration (2.3) and Warnings and Precautions (5.2) ] . Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly."],"pediatric_use":["8.4 Pediatric Use Levothyroxine sodium is indicated in patients from birth to less than 17 years of age: As a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on cognitive development as well as on overall physical growth and maturation. Therefore, initiate levothyroxine sodium therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients [see Warnings and Precautions (5.1) ]. Closely monitor infants during the first 2 weeks of levothyroxine sodium therapy for cardiac overload and arrhythmias."],"effective_time":"20260324","nursing_mothers":["8.2 Lactation Risk Summary Published studies report that levothyroxine is present in human milk following the administration of oral levothyroxine. No adverse effects on the breastfed infant have been reported and there is no information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers with low milk supply. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for levothyroxine sodium and any potential adverse effects on the breastfed infant from levothyroxine sodium or from the underlying maternal condition"],"pharmacodynamics":["12.2 Pharmacodynamics Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the levothyroxine sodium dose is absorbed from the jejunum and upper ileum. The relative bioavailability of levothyroxine sodium tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 93%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7) ] . Distribution Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions (7) ] . Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations (8.1) ] . Elimination Metabolism T4 is slowly eliminated (see Table 10). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation. Excretion Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age. Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients Hormone Ratio in Thyroglobulin Biologic Potency t 1/2 (days) Protein Binding (%) * Levothyroxine (T4) 10 to 20 1 6 to 7 ** 99.96 Liothyronine (T3) 1 4 ≤ 2 99.5 *Includes TBG, TBPA, and TBA ** 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism"],"adverse_reactions":["6 ADVERSE REACTIONS Adverse reactions associated with levothyroxine sodium therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5) and Overdosage (10) ]. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscle weakness, muscle spasm Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with the institution of levothyroxine therapy. Adverse Reactions in Pediatric Patients Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants who have not undergone complete closure of the fontanelles, and in premature closure of the epiphyses in pediatric patients still experiencing growth with resultant compromised adult height. Hypersensitivity Reactions Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur. Adverse reactions associated with levothyroxine sodium therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash. (6) To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS Levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.4) ]. Uncorrected adrenal insufficiency. (4)"],"description_table":["
Table 9. Levothyroxine Sodium Tablet Color Additives
Strength (mcg)Color additive(s)
25FD&C Yellow No. 6 Aluminum Lake
50None
75FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
88FD&C Blue No. 2 Aluminum Lake, FD&C Yellow No. 5 Aluminum Lake
100FD&C Yellow No. 5 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake
112FD&C Red No. 40 Aluminum Lake, Carmine
125FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
137FD&C Blue No. 1 Aluminum Lake
150FD&C Blue No. 2 Aluminum Lake
175FD&C Blue No. 1 Aluminum Lake, Carmine
200FD&C Red No. 40 Aluminum Lake
300D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
"],"drug_interactions":["7 DRUG INTERACTIONS See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium. (7) 7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium (Tables 5 to 8). Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of levothyroxine sodium by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Phosphate Binders (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders may bind to levothyroxine. Administer levothyroxine sodium tablets at least 4 hours apart from these agents. Orlistat Monitor patients treated concomitantly with orlistat and levothyroxine sodium for changes in thyroid function. Bile Acid Sequestrants (e.g., colesevelam, cholestyramine, colestipol) Ion Exchange Resins (e.g., Kayexalate) Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer levothyroxine sodium tablets at least 4 hours prior to these drugs or monitor TSH levels. Proton Pump Inhibitors Sucralfate Antacids (e.g., aluminum & magnesium hydroxides, simethicone) Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately. Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. Potential impact (below): Administration of these agents with levothyroxine sodium results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations. Salicylates (> 2 g/day) Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters. Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism) Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine sodium requirements. Drug or Drug Class Effect Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5’-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine. Table 8. Drugs That May Decrease Conversion of T4 to T3 Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased. Drug or Drug Class Effect Beta-adrenergic antagonists (e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state. Glucocorticoids (e.g., Dexamethasone ≥ 4 mg/day) Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above). Other drugs: Amiodarone Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients. 7.2 Antidiabetic Therapy Addition of levothyroxine sodium therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions (5.5) ] . 7.3 Oral Anticoagulants Levothyroxine sodium increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the levothyroxine sodium dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments. 7.4 Digitalis Glycosides Levothyroxine sodium may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides. 7.5 Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. Levothyroxine sodium may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on levothyroxine sodium may result in increased levothyroxine sodium requirements. 7.6 Ketamine Concurrent use of ketamine and levothyroxine sodium may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients. 7.7 Sympathomimetics Concurrent use of sympathomimetics and levothyroxine sodium may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease. 7.8 Tyrosine-Kinase Inhibitors Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients. 7.9 Drug-Food Interactions Consumption of certain foods may affect levothyroxine sodium absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1) ] . Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of levothyroxine sodium from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability. 7.10 Drug-Laboratory Test Interactions Thyroxine-binding Globulin (TBG) Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000. Biotin Biotin supplementation is known to interfere with thyroid hormone immunoassays that are based on a biotin and streptavidin interaction, which may result in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days prior to thyroid testing.","7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium (Tables 5 to 8). Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of levothyroxine sodium by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Phosphate Binders (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders may bind to levothyroxine. Administer levothyroxine sodium tablets at least 4 hours apart from these agents. Orlistat Monitor patients treated concomitantly with orlistat and levothyroxine sodium for changes in thyroid function. Bile Acid Sequestrants (e.g., colesevelam, cholestyramine, colestipol) Ion Exchange Resins (e.g., Kayexalate) Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer levothyroxine sodium tablets at least 4 hours prior to these drugs or monitor TSH levels. Proton Pump Inhibitors Sucralfate Antacids (e.g., aluminum & magnesium hydroxides, simethicone) Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately. Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration. Potential impact (below): Administration of these agents with levothyroxine sodium results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations. Salicylates (> 2 g/day) Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%. Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters. Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism) Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine sodium requirements. Drug or Drug Class Effect Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5’-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine. Table 8. Drugs That May Decrease Conversion of T4 to T3 Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased. Drug or Drug Class Effect Beta-adrenergic antagonists (e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state. Glucocorticoids (e.g., Dexamethasone ≥ 4 mg/day) Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above). Other drugs: Amiodarone Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.","7.2 Antidiabetic Therapy Addition of levothyroxine sodium therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions (5.5) ] .","7.3 Oral Anticoagulants Levothyroxine sodium increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the levothyroxine sodium dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.","7.4 Digitalis Glycosides Levothyroxine sodium may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.","7.5 Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. Levothyroxine sodium may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on levothyroxine sodium may result in increased levothyroxine sodium requirements.","7.6 Ketamine Concurrent use of ketamine and levothyroxine sodium may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.","7.7 Sympathomimetics Concurrent use of sympathomimetics and levothyroxine sodium may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.","7.8 Tyrosine-Kinase Inhibitors Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients."],"mechanism_of_action":["12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues."],"recent_major_changes":["Dosage and Administration, Important Considerations for Dosing ( 2.2 ) 2/2024 Dosage and Administration, Monitoring TSH and/or Thyroxine (T4) Levels ( 2.4 ) 2/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues. 12.2 Pharmacodynamics Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present. 12.3 Pharmacokinetics Absorption Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the levothyroxine sodium dose is absorbed from the jejunum and upper ileum. The relative bioavailability of levothyroxine sodium tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 93%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7) ] . Distribution Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions (7) ] . Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations (8.1) ] . Elimination Metabolism T4 is slowly eliminated (see Table 10). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation. Excretion Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age. Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients Hormone Ratio in Thyroglobulin Biologic Potency t 1/2 (days) Protein Binding (%) * Levothyroxine (T4) 10 to 20 1 6 to 7 ** 99.96 Liothyronine (T3) 1 4 ≤ 2 99.5 *Includes TBG, TBPA, and TBA ** 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism"],"indications_and_usage":["1 INDICATIONS AND USAGE Hypothyroidism Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium may induce hyperthyroidism [see Warnings and Precautions (5.1) ]. Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets are a L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1) Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1) Limitations of Use: Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Serious risks related to overtreatment or undertreatment with levothyroxine sodium tablets: Titrate the dose of levothyroxine sodium carefully and monitor response to titration. (5.1) Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate levothyroxine sodium at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (2.3 , 5.2 , 8.5) Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma. (5.3) Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium treatment. (5.4) Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy. (5.5) Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose. (5.6) 5.1 Serious Risks Related to Overtreatment or Undertreatment with Levothyroxine Sodium Tablets Levothyroxine sodium tablets has a narrow therapeutic index. Overtreatment or undertreatment with levothyroxine sodium tablets may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism in adult or pediatric patients. In pediatric patients with congenital and acquired hypothyroidism, undertreatment may adversely affect cognitive development and linear growth, and overtreatment is associated with craniosynostosis and acceleration of bone age [Use in Specific Populations (8.4) ]. Titrate the dose of levothyroxine sodium tablets carefully and monitor response to titration to avoid these effects [see Dosage and Administration (2.4)]. Consider the potential for food or drug interactions and adjust the administration or dosage of levothyroxine sodium tablets as needed [see Dosage and Administration (2.1) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. 5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease Over-treatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate levothyroxine sodium therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3) and Use in Specific Populations (8.5) ]. Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive levothyroxine sodium therapy. Monitor patients receiving concomitant levothyroxine sodium and sympathomimetic agents for signs and symptoms of coronary insufficiency. If cardiac symptoms develop or worsen, reduce the levothyroxine sodium tablets dose or withhold for one week and restart at a lower dose. 5.3 Myxedema Coma Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma. 5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with levothyroxine sodium [see Contraindications (4) ] . 5.5 Worsening of Diabetic Control Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing levothyroxine sodium [see Drug Interactions (7.2) ] . 5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of levothyroxine sodium that achieves the desired clinical and biochemical response to mitigate this risk. 5.7 Risk of Allergic Reactions Due to Tartrazine This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.","5.1 Serious Risks Related to Overtreatment or Undertreatment with Levothyroxine Sodium Tablets Levothyroxine sodium tablets has a narrow therapeutic index. Overtreatment or undertreatment with levothyroxine sodium tablets may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism in adult or pediatric patients. In pediatric patients with congenital and acquired hypothyroidism, undertreatment may adversely affect cognitive development and linear growth, and overtreatment is associated with craniosynostosis and acceleration of bone age [Use in Specific Populations (8.4) ]. Titrate the dose of levothyroxine sodium tablets carefully and monitor response to titration to avoid these effects [see Dosage and Administration (2.4)]. Consider the potential for food or drug interactions and adjust the administration or dosage of levothyroxine sodium tablets as needed [see Dosage and Administration (2.1) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ].","5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease Over-treatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate levothyroxine sodium therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3) and Use in Specific Populations (8.5) ]. Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive levothyroxine sodium therapy. Monitor patients receiving concomitant levothyroxine sodium and sympathomimetic agents for signs and symptoms of coronary insufficiency. If cardiac symptoms develop or worsen, reduce the levothyroxine sodium tablets dose or withhold for one week and restart at a lower dose.","5.3 Myxedema Coma Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.","5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with levothyroxine sodium [see Contraindications (4) ] .","5.5 Worsening of Diabetic Control Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing levothyroxine sodium [see Drug Interactions (7.2) ] .","5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of levothyroxine sodium that achieves the desired clinical and biochemical response to mitigate this risk.","5.7 Risk of Allergic Reactions Due to Tartrazine This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.","7.9 Drug-Food Interactions Consumption of certain foods may affect levothyroxine sodium absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1) ] . Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of levothyroxine sodium from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.","7.10 Drug-Laboratory Test Interactions Thyroxine-binding Globulin (TBG) Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000. Biotin Biotin supplementation is known to interfere with thyroid hormone immunoassays that are based on a biotin and streptavidin interaction, which may result in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days prior to thyroid testing."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in animals to evaluate the carcinogenic potential of levothyroxine have not been performed. Studies to evaluate mutagenic potential and animal fertility have not been performed."],"pharmacokinetics_table":["
Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients
HormoneRatio in ThyroglobulinBiologic Potencyt 1/2(days) Protein Binding (%) *
Levothyroxine (T4)10 to 2016 to 7 **99.96
Liothyronine (T3)14≤ 299.5
*Includes TBG, TBPA, and TBA ** 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism
"],"drug_interactions_table":["
Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism)
Potential impact: Concurrent use may reduce the efficacy of levothyroxine sodium by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.
Drug or Drug ClassEffect
Phosphate Binders (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders may bind to levothyroxine. Administer levothyroxine sodium tablets at least 4 hours apart from these agents.
OrlistatMonitor patients treated concomitantly with orlistat and levothyroxine sodium for changes in thyroid function.
Bile Acid Sequestrants (e.g., colesevelam, cholestyramine, colestipol) Ion Exchange Resins (e.g., Kayexalate) Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer levothyroxine sodium tablets at least 4 hours prior to these drugs or monitor TSH levels.
Proton Pump Inhibitors Sucralfate Antacids (e.g., aluminum & magnesium hydroxides, simethicone) Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately.
","
Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)
Drug or Drug ClassEffect
Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration.
Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration.
Potential impact (below): Administration of these agents with levothyroxine sodium results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.
Salicylates (> 2 g/day)Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.
Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.
","
Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)
Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine sodium requirements.
Drug or Drug ClassEffect
Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5’-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.
","
Table 8. Drugs That May Decrease Conversion of T4 to T3
Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.
Drug or Drug ClassEffect
Beta-adrenergic antagonists (e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.
Glucocorticoids (e.g., Dexamethasone ≥4 mg/day) Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).
Other drugs: Amiodarone Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.
","
Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism)
Potential impact: Concurrent use may reduce the efficacy of levothyroxine sodium by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.
Drug or Drug ClassEffect
Phosphate Binders (e.g., calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders may bind to levothyroxine. Administer levothyroxine sodium tablets at least 4 hours apart from these agents.
OrlistatMonitor patients treated concomitantly with orlistat and levothyroxine sodium for changes in thyroid function.
Bile Acid Sequestrants (e.g., colesevelam, cholestyramine, colestipol) Ion Exchange Resins (e.g., Kayexalate) Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer levothyroxine sodium tablets at least 4 hours prior to these drugs or monitor TSH levels.
Proton Pump Inhibitors Sucralfate Antacids (e.g., aluminum & magnesium hydroxides, simethicone) Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately.
","
Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)
Drug or Drug ClassEffect
Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin / Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration.
Androgens / Anabolic Steroids Asparaginase Glucocorticoids Slow-Release Nicotinic Acid These drugs may decrease serum TBG concentration.
Potential impact (below): Administration of these agents with levothyroxine sodium results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.
Salicylates (> 2 g/day)Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.
Other drugs: Carbamazepine Furosemide (> 80 mg IV) Heparin Hydantoins Non-Steroidal Anti-inflammatory Drugs - Fenamates These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.
","
Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)
Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine sodium requirements.
Drug or Drug ClassEffect
Phenobarbital Rifampin Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5’-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.
","
Table 8. Drugs That May Decrease Conversion of T4 to T3
Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.
Drug or Drug ClassEffect
Beta-adrenergic antagonists (e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.
Glucocorticoids (e.g., Dexamethasone ≥4 mg/day) Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).
Other drugs: Amiodarone Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Inform the patient of the following information to aid in the safe and effective use of Levothyroxine sodium tablets: Dosing and Administration Instruct patients to take levothyroxine sodium tablets only as directed by their healthcare provider. Instruct patients to take levothyroxine sodium tablets as a single dose, preferably on an empty stomach, one-half to one hour before breakfast with a full glass of water to avoid choking or gagging. Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take levothyroxine sodium tablets within 4 hours of these agents. Instruct patients to notify their healthcare provider if they are pregnant or breastfeeding or are thinking of becoming pregnant while taking levothyroxine sodium tablets. Important Information Inform patients that it may take several weeks before they notice an improvement in symptoms. Inform patients that the levothyroxine in levothyroxine sodium tablets is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life. Inform patients that levothyroxine sodium tablets should not be used as a primary or adjunctive therapy in a weight control program. Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations. Instruct patients to discontinue biotin or any biotin-containing supplements for at least 2 days before thyroid function testing is conducted. Instruct patients to notify their physician of any other medical conditions they may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while they are taking levothyroxine sodium tablets. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently. Instruct patients to notify their physician or dentist that they are taking levothyroxine sodium tablets prior to any surgery. Adverse Reactions Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event. Inform patients that partial hair loss may occur rarely during the first few months of levothyroxine sodium tablets therapy, but this is usually temporary. Manufactured For: Accord Healthcare, Inc., 8041 Arco Corporate Drive, Suite 200, Raleigh, NC 27617, USA. Manufactured By: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun, Uttarakhand 248197, India (IND) 80 3024 5 8619358 Issued June 2024"],"spl_unclassified_section":[""],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast with a full glass of water. (2.1) Administer at least 4 hours before or after drugs that are known to interfere with absorption. (2.1) Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1) Advise patients to stop biotin and biotin-containing supplements at least 2 days before assessing TSH and/or T4 levels. (2.2) Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4 to 6 weeks. (2.2) See full prescribing information for dosing in specific patient populations. (2.3) Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4) 2.1 Important Administration Instructions Administer levothyroxine sodium tablets as a single daily dose, on an empty stomach, one-half to one hour before breakfast with a full glass of water to avoid choking or gagging [see Adverse Reactions (6) ]. Administer levothyroxine sodium tablets at least 4 hours before or after drugs known to interfere with levothyroxine sodium absorption [see Drug Interactions (7.1) ]. Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect levothyroxine sodium tablets absorption [see Dosage and Administration (2.2 and 2.3) , Drug Interactions (7.9), and Clinical Pharmacology (12.3) ]. Administer levothyroxine sodium tablets to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper. Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of levothyroxine sodium tablets, such as soybean-based infant formula [see Drug Interactions (7.9) ]. 2.2 Important Considerations for Dosing The dosage of levothyroxine sodium tablets for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3) , Warnings and Precautions (5) , and Drug Interactions (7) ] . Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4) ]. For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (2.3) ]. For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of levothyroxine sodium dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate levothyroxine sodium tablets dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (2.3) ]. Inquire whether patients are taking biotin or biotin-containing supplements. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and/or T4 levels [see Dosage and Administration (2.4) and Drug Interactions (7.10) ]. The peak therapeutic effect of a given dose of levothyroxine sodium tablets may not be attained for 4 to 6 weeks. 2.3 Recommended Dosage and Titration Primary, Secondary, and Tertiary Hypothyroidism in Adults The recommended starting daily dosage of levothyroxine sodium tablets in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms. Dosage titration is based on serum TSH or free-T4 [see Dosage and Administration (2.2) ]. Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults* *Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1) and Drug Interactions (7) ]. Patient Population Starting Dosage Dosage Titration Based on serum TSH or Free-T4 Adults diagnosed with hypothyroidism Full replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid. Adults at risk for atrial fibrillation or with underlying cardiac disease Lower starting dose (less than 1.6 mcg/kg/day) Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid. Geriatric patients Lower starting dose (less than 1.6 mcg/kg/day) Primary, Secondary, and Tertiary Hypothyroidism in Pediatric Patients The recommended starting daily dosage of levothyroxine sodium tablets in pediatric patients with primary, secondary, or tertiary hypothyroidism is based on body weight and changes with age as described in Table 2. Titrate the dosage (every 2 weeks) as needed based on serum TSH or free-T4 until the patient is euthyroid [see Dosage and Administration (2.2) ]. Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients Age Starting Daily Dosage Per Kg Body Weight* 0 to 3 months 10 to 15 mcg/kg/day 3 to 6 months 8 to 10 mcg/kg/day 6 to 12 months 6 to 8 mcg/kg/day 1 to 5 years 5 to 6 mcg/kg/day 6 to 12 years 4 to 5 mcg/kg/day Greater than 12 years but growth and puberty incomplete 2 to 3 mcg/kg/day Growth and puberty complete 1.6 mcg/kg/day *Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4) ] . Pediatric Patients from Birth to 3 Months of Age at Risk for Cardiac Failure Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response. Pediatric Patients at Risk for Hyperactivity To minimize the risk of hyperactivity, start at one-fourth the recommended full replacement dosage, and increase on a weekly basis by one-fourth the full recommended replacement dosage until the full recommended replacement dosage is reached. Hypothyroidism in Pregnant Patients For pregnant patients with pre-existing hypothyroidism, measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In pregnant patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. The recommended daily dosage of levothyroxine sodium tablets in pregnant patients is described in Table 3. Table 3. Levothyroxine Sodium Tablet Dosing Guidelines for Hypothyroidism in Pregnant Patients Patient Population Starting Dosage Dose Adjustment and Titration Pre-existing primary hypothyroidism with serum TSH above normal trimester- specific range Pre-pregnancy dosage may increase during pregnancy Increase levothyroxine sodium dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce levothyroxine sodium dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum. New onset hypothyroidism (TSH ≥10 mIU per liter) 1.6 mcg/kg/day Monitor serum TSH every 4 weeks and adjust levothyroxine sodium dosage until serum TSH is within normal trimester-specific range. New onset hypothyroidism (TSH < 10 mIU per liter) 1.0 mcg/kg/day TSH Suppression in Well-differentiated Thyroid Cancer in Adult and Pediatric Patients The levothyroxine sodium dosage is based on the target level of TSH suppression for the stage and clinical status of thyroid cancer. 2.4 Monitoring TSH and/or Thyroxine (T4) Levels Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Biotin supplementation may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days before assessing TSH and/or T4 levels [see Drug Interactions (7.10) ] . Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of levothyroxine sodium may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors. Adults In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status. Pediatric Patients In patients with hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals. The general aim of therapy is to normalize the serum TSH level. TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of levothyroxine sodium therapy and/or of the serum TSH to decrease below 20 mIU per litre within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of levothyroxine sodium [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4) ] . Secondary and Tertiary Hypothyroidism Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.","2.1 Important Administration Instructions Administer levothyroxine sodium tablets as a single daily dose, on an empty stomach, one-half to one hour before breakfast with a full glass of water to avoid choking or gagging [see Adverse Reactions (6) ]. Administer levothyroxine sodium tablets at least 4 hours before or after drugs known to interfere with levothyroxine sodium absorption [see Drug Interactions (7.1) ]. Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect levothyroxine sodium tablets absorption [see Dosage and Administration (2.2 and 2.3) , Drug Interactions (7.9), and Clinical Pharmacology (12.3) ]. Administer levothyroxine sodium tablets to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper. Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of levothyroxine sodium tablets, such as soybean-based infant formula [see Drug Interactions (7.9) ].","2.2 Important Considerations for Dosing The dosage of levothyroxine sodium tablets for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3) , Warnings and Precautions (5) , and Drug Interactions (7) ] . Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4) ]. For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration (2.3) ]. For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of levothyroxine sodium dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate levothyroxine sodium tablets dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration (2.3) ]. Inquire whether patients are taking biotin or biotin-containing supplements. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and/or T4 levels [see Dosage and Administration (2.4) and Drug Interactions (7.10) ]. The peak therapeutic effect of a given dose of levothyroxine sodium tablets may not be attained for 4 to 6 weeks.","2.3 Recommended Dosage and Titration Primary, Secondary, and Tertiary Hypothyroidism in Adults The recommended starting daily dosage of levothyroxine sodium tablets in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms. Dosage titration is based on serum TSH or free-T4 [see Dosage and Administration (2.2) ]. Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults* *Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1) and Drug Interactions (7) ]. Patient Population Starting Dosage Dosage Titration Based on serum TSH or Free-T4 Adults diagnosed with hypothyroidism Full replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid. Adults at risk for atrial fibrillation or with underlying cardiac disease Lower starting dose (less than 1.6 mcg/kg/day) Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid. Geriatric patients Lower starting dose (less than 1.6 mcg/kg/day) Primary, Secondary, and Tertiary Hypothyroidism in Pediatric Patients The recommended starting daily dosage of levothyroxine sodium tablets in pediatric patients with primary, secondary, or tertiary hypothyroidism is based on body weight and changes with age as described in Table 2. Titrate the dosage (every 2 weeks) as needed based on serum TSH or free-T4 until the patient is euthyroid [see Dosage and Administration (2.2) ]. Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients Age Starting Daily Dosage Per Kg Body Weight* 0 to 3 months 10 to 15 mcg/kg/day 3 to 6 months 8 to 10 mcg/kg/day 6 to 12 months 6 to 8 mcg/kg/day 1 to 5 years 5 to 6 mcg/kg/day 6 to 12 years 4 to 5 mcg/kg/day Greater than 12 years but growth and puberty incomplete 2 to 3 mcg/kg/day Growth and puberty complete 1.6 mcg/kg/day *Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4) ] . Pediatric Patients from Birth to 3 Months of Age at Risk for Cardiac Failure Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response. Pediatric Patients at Risk for Hyperactivity To minimize the risk of hyperactivity, start at one-fourth the recommended full replacement dosage, and increase on a weekly basis by one-fourth the full recommended replacement dosage until the full recommended replacement dosage is reached. Hypothyroidism in Pregnant Patients For pregnant patients with pre-existing hypothyroidism, measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In pregnant patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. The recommended daily dosage of levothyroxine sodium tablets in pregnant patients is described in Table 3. Table 3. Levothyroxine Sodium Tablet Dosing Guidelines for Hypothyroidism in Pregnant Patients Patient Population Starting Dosage Dose Adjustment and Titration Pre-existing primary hypothyroidism with serum TSH above normal trimester- specific range Pre-pregnancy dosage may increase during pregnancy Increase levothyroxine sodium dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce levothyroxine sodium dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum. New onset hypothyroidism (TSH ≥10 mIU per liter) 1.6 mcg/kg/day Monitor serum TSH every 4 weeks and adjust levothyroxine sodium dosage until serum TSH is within normal trimester-specific range. New onset hypothyroidism (TSH < 10 mIU per liter) 1.0 mcg/kg/day TSH Suppression in Well-differentiated Thyroid Cancer in Adult and Pediatric Patients The levothyroxine sodium dosage is based on the target level of TSH suppression for the stage and clinical status of thyroid cancer.","Primary, Secondary, and Tertiary Hypothyroidism in Adults The recommended starting daily dosage of levothyroxine sodium tablets in adults with primary, secondary, or tertiary hypothyroidism is based on age and comorbid cardiac conditions, as described in Table 1. For patients at risk of atrial fibrillation or patients with underlying cardiac disease, start with a lower dosage and titrate the dosage more slowly to avoid exacerbation of cardiac symptoms. Dosage titration is based on serum TSH or free-T4 [see Dosage and Administration (2.2) ]. Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults* *Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1) and Drug Interactions (7) ]. Patient Population Starting Dosage Dosage Titration Based on serum TSH or Free-T4 Adults diagnosed with hypothyroidism Full replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid. Adults at risk for atrial fibrillation or with underlying cardiac disease Lower starting dose (less than 1.6 mcg/kg/day) Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid. Geriatric patients Lower starting dose (less than 1.6 mcg/kg/day) Primary, Secondary, and Tertiary Hypothyroidism in Pediatric Patients The recommended starting daily dosage of levothyroxine sodium tablets in pediatric patients with primary, secondary, or tertiary hypothyroidism is based on body weight and changes with age as described in Table 2. Titrate the dosage (every 2 weeks) as needed based on serum TSH or free-T4 until the patient is euthyroid [see Dosage and Administration (2.2) ]. Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients Age Starting Daily Dosage Per Kg Body Weight* 0 to 3 months 10 to 15 mcg/kg/day 3 to 6 months 8 to 10 mcg/kg/day 6 to 12 months 6 to 8 mcg/kg/day 1 to 5 years 5 to 6 mcg/kg/day 6 to 12 years 4 to 5 mcg/kg/day Greater than 12 years but growth and puberty incomplete 2 to 3 mcg/kg/day Growth and puberty complete 1.6 mcg/kg/day *Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4) ] . Pediatric Patients from Birth to 3 Months of Age at Risk for Cardiac Failure Start at a lower starting dosage and increase the dosage every 4 to 6 weeks as needed based on clinical and laboratory response. Pediatric Patients at Risk for Hyperactivity To minimize the risk of hyperactivity, start at one-fourth the recommended full replacement dosage, and increase on a weekly basis by one-fourth the full recommended replacement dosage until the full recommended replacement dosage is reached. Hypothyroidism in Pregnant Patients For pregnant patients with pre-existing hypothyroidism, measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In pregnant patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. The recommended daily dosage of levothyroxine sodium tablets in pregnant patients is described in Table 3. Table 3. Levothyroxine Sodium Tablet Dosing Guidelines for Hypothyroidism in Pregnant Patients Patient Population Starting Dosage Dose Adjustment and Titration Pre-existing primary hypothyroidism with serum TSH above normal trimester- specific range Pre-pregnancy dosage may increase during pregnancy Increase levothyroxine sodium dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce levothyroxine sodium dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum. New onset hypothyroidism (TSH ≥10 mIU per liter) 1.6 mcg/kg/day Monitor serum TSH every 4 weeks and adjust levothyroxine sodium dosage until serum TSH is within normal trimester-specific range. New onset hypothyroidism (TSH < 10 mIU per liter) 1.0 mcg/kg/day TSH Suppression in Well-differentiated Thyroid Cancer in Adult and Pediatric Patients The levothyroxine sodium dosage is based on the target level of TSH suppression for the stage and clinical status of thyroid cancer.","2.4 Monitoring TSH and/or Thyroxine (T4) Levels Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Biotin supplementation may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days before assessing TSH and/or T4 levels [see Drug Interactions (7.10) ] . Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of levothyroxine sodium may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors. Adults In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status. Pediatric Patients In patients with hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals. The general aim of therapy is to normalize the serum TSH level. TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of levothyroxine sodium therapy and/or of the serum TSH to decrease below 20 mIU per litre within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of levothyroxine sodium [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4) ] . Secondary and Tertiary Hypothyroidism Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.","Adults In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.","Pediatric Patients In patients with hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals. The general aim of therapy is to normalize the serum TSH level. TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of levothyroxine sodium therapy and/or of the serum TSH to decrease below 20 mIU per litre within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of levothyroxine sodium [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4) ] .","Secondary and Tertiary Hypothyroidism Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients."],"spl_product_data_elements":["Levothyroxine sodium Levothyroxine Sodium MICROCRYSTALLINE CELLULOSE MAGNESIUM OXIDE SODIUM STARCH GLYCOLATE TYPE A POTATO SODIUM STEARYL FUMARATE BLUE 1 CARMINIC ACID LEVOTHYROXINE SODIUM LEVOTHYROXINE LEVOTHYROXINE SODIUM ANHYDROUS Lilac P;10"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS All tablets having functional scoring Levothyroxine sodium tablets USP are available as follows (Table 4): Table 4: Levothyroxine Sodium Tablet Strengths and Identifying Features Tablet Strength Tablet Description 25 mcg Round shaped, Orange colored, uncoated tablets, break line on both side and debossed with \"P\" and \"1\" on one side and plain on other side. 50 mcg Round shaped, White colored, uncoated tablets, break line on both side and debossed with \"P\" and \"2\" on one side and plain on other side. 75 mcg Round shaped, Violet colored, uncoated tablets, break line on both side and debossed with \"P\" and \"3\" on one side and plain on other side. 88 mcg Round shaped, Olive colored, uncoated tablets, break line on both side and debossed with \"P\" and \"4\" on one side and plain on other side. 100 mcg Round shaped, Yellow colored, uncoated tablets, break line on both side and debossed with \"P\" and \"14\" on one side and plain on other side. 112 mcg Round shaped, Rose colored, uncoated tablets, break line on both side and debossed with \"P\" and \"6\" on one side and plain on other side. 125 mcg Round shaped, Brown colored, uncoated tablets, break line on both side and debossed with \"P\" and \"7\" on one side and plain on other side. 137 mcg Round shaped, Turquoise colored, uncoated tablets, break line on both side and debossed with \"P\" and \"8\" on one side and plain on other side. 150 mcg Round shaped, Blue colored, uncoated tablets, break line on both side and debossed with \"P\" and \"9\" on one side and plain on other side. 175 mcg Round shaped, Lilac colored, uncoated tablets, break line on both side and debossed with \"P\" and \"10\" on one side and plain on other side. 200 mcg Round shaped, Pink colored, uncoated tablets, break line on both side and debossed with \"P\" and \"11\" on one side and plain on other side. 300 mcg Round shaped, Green colored, uncoated tablets, break line on both side and debossed with \"P\" and \"12\" on one side and plain on other side. Tablets (Functional Scoring): 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg (3)"],"recent_major_changes_table":["
Dosage and Administration, Important Considerations for Dosing ( 2.2) 2/2024
Dosage and Administration, Monitoring TSH and/or Thyroxine (T4) Levels ( 2.4) 2/2024
"],"clinical_pharmacology_table":["
Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients
HormoneRatio in ThyroglobulinBiologic Potencyt 1/2(days) Protein Binding (%) *
Levothyroxine (T4)10 to 2016 to 7 **99.96
Liothyronine (T3)14≤ 299.5
*Includes TBG, TBPA, and TBA ** 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy may require the use of higher doses of levothyroxine sodium. (2.3 , 8.1) 8.1 Pregnancy Risk Summary The clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and levothyroxine sodium dosage adjusted during pregnancy (see Clinical Considerations) . Animal reproductive studies have not been conducted with levothyroxine sodium. Levothyroxine sodium should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre‑eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development. Dose Adjustments During Pregnancy and the Postpartum Period Pregnancy may increase levothyroxine sodium requirements. Serum TSH levels should be monitored and the levothyroxine sodium dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the levothyroxine sodium dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration (2.3) ]. 8.2 Lactation Risk Summary Published studies report that levothyroxine is present in human milk following the administration of oral levothyroxine. No adverse effects on the breastfed infant have been reported and there is no information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers with low milk supply. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for levothyroxine sodium and any potential adverse effects on the breastfed infant from levothyroxine sodium or from the underlying maternal condition 8.4 Pediatric Use Levothyroxine sodium is indicated in patients from birth to less than 17 years of age: As a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on cognitive development as well as on overall physical growth and maturation. Therefore, initiate levothyroxine sodium therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients [see Warnings and Precautions (5.1) ]. Closely monitor infants during the first 2 weeks of levothyroxine sodium therapy for cardiac overload and arrhythmias. 8.5 Geriatric Use Because of the increased prevalence of cardiovascular disease among the elderly, initiate levothyroxine sodium at less than the full replacement dose [see Dosage and Administration (2.3) and Warnings and Precautions (5.2) ] . Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly."],"dosage_and_administration_table":["
Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults*
*Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1)and Drug Interactions (7)].
Patient PopulationStarting DosageDosage Titration Based on serum TSH or Free-T4
Adults diagnosed with hypothyroidismFull replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid.
Adults at risk for atrial fibrillation or with underlying cardiac diseaseLower starting dose (less than 1.6 mcg/kg/day)Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid.
Geriatric patientsLower starting dose (less than 1.6 mcg/kg/day)
","
Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients
AgeStarting Daily Dosage Per Kg Body Weight*
0 to 3 months10 to 15 mcg/kg/day
3 to 6 months8 to 10 mcg/kg/day
6 to 12 months6 to 8 mcg/kg/day
1 to 5 years5 to 6 mcg/kg/day
6 to 12 years4 to 5 mcg/kg/day
Greater than 12 years but growth and puberty incomplete2 to 3 mcg/kg/day
Growth and puberty complete1.6 mcg/kg/day
*Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)] .
","
Table 3. Levothyroxine Sodium Tablet Dosing Guidelines for Hypothyroidism in Pregnant Patients
Patient PopulationStarting DosageDose Adjustment and Titration
Pre-existing primary hypothyroidism with serum TSH above normal trimester- specific rangePre-pregnancy dosage may increase during pregnancyIncrease levothyroxine sodium dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce levothyroxine sodium dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum.
New onset hypothyroidism (TSH ≥10 mIU per liter)1.6 mcg/kg/dayMonitor serum TSH every 4 weeks and adjust levothyroxine sodium dosage until serum TSH is within normal trimester-specific range.
New onset hypothyroidism (TSH < 10 mIU per liter)1.0 mcg/kg/day
","
Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults*
*Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1)and Drug Interactions (7)].
Patient PopulationStarting DosageDosage Titration Based on serum TSH or Free-T4
Adults diagnosed with hypothyroidismFull replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid.
Adults at risk for atrial fibrillation or with underlying cardiac diseaseLower starting dose (less than 1.6 mcg/kg/day)Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid.
Geriatric patientsLower starting dose (less than 1.6 mcg/kg/day)
","
Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients
AgeStarting Daily Dosage Per Kg Body Weight*
0 to 3 months10 to 15 mcg/kg/day
3 to 6 months8 to 10 mcg/kg/day
6 to 12 months6 to 8 mcg/kg/day
1 to 5 years5 to 6 mcg/kg/day
6 to 12 years4 to 5 mcg/kg/day
Greater than 12 years but growth and puberty incomplete2 to 3 mcg/kg/day
Growth and puberty complete1.6 mcg/kg/day
*Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)] .
","
Table 3. Levothyroxine Sodium Tablet Dosing Guidelines for Hypothyroidism in Pregnant Patients
Patient PopulationStarting DosageDose Adjustment and Titration
Pre-existing primary hypothyroidism with serum TSH above normal trimester- specific rangePre-pregnancy dosage may increase during pregnancyIncrease levothyroxine sodium dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce levothyroxine sodium dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum.
New onset hypothyroidism (TSH ≥10 mIU per liter)1.6 mcg/kg/dayMonitor serum TSH every 4 weeks and adjust levothyroxine sodium dosage until serum TSH is within normal trimester-specific range.
New onset hypothyroidism (TSH < 10 mIU per liter)1.0 mcg/kg/day
","
Table 1. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Adults*
*Dosages greater than 200 mcg/day are seldom required. An inadequate response to daily dosages greater than 300 mcg/day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors [see Dosage and Administration (2.1)and Drug Interactions (7)].
Patient PopulationStarting DosageDosage Titration Based on serum TSH or Free-T4
Adults diagnosed with hypothyroidismFull replacement dose is 1.6 mcg/kg/day. Some patients require a lower starting dose. Titrate dosage by 12.5 to 25 mcg increments every 4 to 6 weeks, as needed until the patient is euthyroid.
Adults at risk for atrial fibrillation or with underlying cardiac diseaseLower starting dose (less than 1.6 mcg/kg/day)Titrate dosage every 6 to 8 weeks, as needed until the patient is euthyroid.
Geriatric patientsLower starting dose (less than 1.6 mcg/kg/day)
","
Table 2. Levothyroxine Sodium Tablets Dosing Guidelines for Hypothyroidism in Pediatric Patients
AgeStarting Daily Dosage Per Kg Body Weight*
0 to 3 months10 to 15 mcg/kg/day
3 to 6 months8 to 10 mcg/kg/day
6 to 12 months6 to 8 mcg/kg/day
1 to 5 years5 to 6 mcg/kg/day
6 to 12 years4 to 5 mcg/kg/day
Greater than 12 years but growth and puberty incomplete2 to 3 mcg/kg/day
Growth and puberty complete1.6 mcg/kg/day
*Adjust dosage based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)] .
","
Table 3. Levothyroxine Sodium Tablet Dosing Guidelines for Hypothyroidism in Pregnant Patients
Patient PopulationStarting DosageDose Adjustment and Titration
Pre-existing primary hypothyroidism with serum TSH above normal trimester- specific rangePre-pregnancy dosage may increase during pregnancyIncrease levothyroxine sodium dosage by 12.5 to 25 mcg per day. Monitor TSH every 4 weeks until a stable dose is reached and serum TSH is within normal trimester-specific range. Reduce levothyroxine sodium dosage to pre-pregnancy levels immediately after delivery. Monitor serum TSH 4 to 8 weeks postpartum.
New onset hypothyroidism (TSH ≥10 mIU per liter)1.6 mcg/kg/dayMonitor serum TSH every 4 weeks and adjust levothyroxine sodium dosage until serum TSH is within normal trimester-specific range.
New onset hypothyroidism (TSH < 10 mIU per liter)1.0 mcg/kg/day
"],"dosage_forms_and_strengths_table":["
Table 4: Levothyroxine Sodium Tablet Strengths and Identifying Features
Tablet StrengthTablet Description
25 mcgRound shaped, Orange colored, uncoated tablets, break line on both side and debossed with "P" and "1" on one side and plain on other side.
50 mcgRound shaped, White colored, uncoated tablets, break line on both side and debossed with "P" and "2" on one side and plain on other side.
75 mcgRound shaped, Violet colored, uncoated tablets, break line on both side and debossed with "P" and "3" on one side and plain on other side.
88 mcgRound shaped, Olive colored, uncoated tablets, break line on both side and debossed with "P" and "4" on one side and plain on other side.
100 mcgRound shaped, Yellow colored, uncoated tablets, break line on both side and debossed with "P" and "14" on one side and plain on other side.
112 mcgRound shaped, Rose colored, uncoated tablets, break line on both side and debossed with "P" and "6" on one side and plain on other side.
125 mcgRound shaped, Brown colored, uncoated tablets, break line on both side and debossed with "P" and "7" on one side and plain on other side.
137 mcgRound shaped, Turquoise colored, uncoated tablets, break line on both side and debossed with "P" and "8" on one side and plain on other side.
150 mcgRound shaped, Blue colored, uncoated tablets, break line on both side and debossed with "P" and "9" on one side and plain on other side.
175 mcgRound shaped, Lilac colored, uncoated tablets, break line on both side and debossed with "P" and "10" on one side and plain on other side.
200 mcgRound shaped, Pink colored, uncoated tablets, break line on both side and debossed with "P" and "11" on one side and plain on other side.
300 mcgRound shaped, Green colored, uncoated tablets, break line on both side and debossed with "P" and "12" on one side and plain on other side.
"],"package_label_principal_display_panel":["LEVOTHYROXINE SODIUM Label Image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in animals to evaluate the carcinogenic potential of levothyroxine have not been performed. Studies to evaluate mutagenic potential and animal fertility have not been performed."]},"tags":[],"safety":{"boxedWarnings":["WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. Thyroid hormones, including levothyroxine sodium, should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity (6 , 10) ."],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"25845 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"22032 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"20559 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"18801 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"18175 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"16221 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"15941 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"15431 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"13160 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"12981 reports"}],"drugInteractions":[{"drug":"Phosphate binders (calcium carbonate, ferrous sulfate, sevelamer, lanthanum)","severity":"Moderate","mechanism":"Phosphate binders bind to levothyroxine, delaying or preventing absorption","management":"Administer levothyroxine sodium tablets at least 4 hours apart from these agents","clinicalEffect":"Reduced efficacy of levothyroxine sodium, potentially resulting in hypothyroidism"},{"drug":"Orlistat","severity":"Moderate","mechanism":"Affects levothyroxine absorption","management":"Monitor patients treated concomitantly with orlistat and levothyroxine sodium for changes in thyroid function","clinicalEffect":"Changes in thyroid function"},{"drug":"Bile acid sequestrants (colesevelam, cholestyramine, colestipol)","severity":"Moderate","mechanism":"Decrease levothyroxine absorption","management":"Administer levothyroxine sodium tablets at least 4 hours prior to these drugs or monitor TSH levels","clinicalEffect":"Reduced efficacy of levothyroxine sodium"},{"drug":"Ion exchange resins (Kayexalate)","severity":"Moderate","mechanism":"Decrease levothyroxine absorption","management":"Administer levothyroxine sodium tablets at least 4 hours prior to these drugs or monitor TSH levels","clinicalEffect":"Reduced efficacy of levothyroxine sodium"},{"drug":"Proton pump inhibitors","severity":"Moderate","mechanism":"Cause hypochlorhydria and affect intragastric pH, reducing levothyroxine absorption","management":"Monitor patients appropriately","clinicalEffect":"Reduced levothyroxine absorption"},{"drug":"Sucralfate","severity":"Moderate","mechanism":"Affects intragastric pH and reduces levothyroxine absorption","management":"Monitor patients appropriately","clinicalEffect":"Reduced levothyroxine absorption"},{"drug":"Antacids (aluminum & magnesium hydroxides, simethicone)","severity":"Moderate","mechanism":"Affect intragastric pH and reduce levothyroxine absorption","management":"Monitor patients appropriately","clinicalEffect":"Reduced levothyroxine absorption"}],"commonSideEffects":[{"effect":"Hypertension","drugRate":"6.2%","placeboRate":"","totalAtRisk":419,"totalAffected":26,"trialsReporting":1},{"effect":"Tachycardia","drugRate":"3.8%","placeboRate":"","totalAtRisk":419,"totalAffected":16,"trialsReporting":1},{"effect":"ANXIETY","drugRate":"5.7%","placeboRate":"","totalAtRisk":141,"totalAffected":8,"trialsReporting":1},{"effect":"Atrial fibrillation","drugRate":"1.7%","placeboRate":"","totalAtRisk":419,"totalAffected":7,"trialsReporting":1},{"effect":"FATIGUE","drugRate":"5.0%","placeboRate":"","totalAtRisk":141,"totalAffected":7,"trialsReporting":1},{"effect":"Ventricular ectopy","drugRate":"1.2%","placeboRate":"","totalAtRisk":419,"totalAffected":5,"trialsReporting":1},{"effect":"Ventricular tachycardia","drugRate":"1.0%","placeboRate":"","totalAtRisk":419,"totalAffected":4,"trialsReporting":1},{"effect":"Misc/Other","drugRate":"1.0%","placeboRate":"","totalAtRisk":419,"totalAffected":4,"trialsReporting":1}],"contraindications":["Uncorrected adrenal insufficiency"],"specialPopulations":{"Pregnancy":"Pregnancy may require the use of higher doses of levothyroxine sodium. Clinical experience in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. TSH levels may increase during pregnancy and should be monitored with levothyroxine sodium dosage adjusted accordingly. Levothyroxine sodium should not be discontinued during pregnancy. Maternal hypothyroidism during pregnancy is associated with higher rates of spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may adversely affect fetal neurocognitive development. Postpartum, levothyroxine sodium dosage should return to the pre-pregnancy dose immediately after delivery.","Geriatric use":"Because of increased prevalence of cardiovascular disease among the elderly, initiate levothyroxine sodium at less than the full replacement dose. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common arrhythmia observed with levothyroxine overtreatment in the elderly.","Paediatric use":"Levothyroxine sodium is indicated in patients from birth to less than 17 years of age as replacement therapy in primary, secondary, and tertiary congenital or acquired hypothyroidism, and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Rapid restoration of normal serum T4 concentrations is essential for preventing adverse effects of congenital hypothyroidism on cognitive development and overall physical growth and maturation. Initiate levothyroxine sodium therapy immediately upon diagnosis. Levothyroxine is generally continued for life. Closely monitor infants during the first 2 weeks of levothyroxine sodium therapy for cardiac overload and arrhythmias.","Renal impairment":"Not addressed in provided text","Hepatic impairment":"Not addressed in provided text"}},"trials":[],"_chembl":null,"aliases":[],"patents":[{"applNo":"N210632","source":"FDA Orange Book","status":"Active","expires":"Dec 1, 2036","territory":"US","drugProduct":true,"patentNumber":"9782376","drugSubstance":false},{"applNo":"N210632","source":"FDA Orange Book","status":"Active","expires":"Dec 1, 2036","territory":"US","drugProduct":true,"patentNumber":"11135190","drugSubstance":false},{"applNo":"N210632","source":"FDA Orange Book","status":"Active","expires":"Dec 1, 2036","territory":"US","drugProduct":true,"patentNumber":"10398669","drugSubstance":false},{"type":"Method of Use","number":"11241382","applicant":"IBSA INSTITUT BIOCHIMIQUE SA","territory":"US","tradeName":"TIROSINT-SOL","expiryDate":"2039-09-17"},{"type":"Formulation","number":"10231931","applicant":"GENUS LIFE SCIENCES INC","territory":"US","tradeName":"LEVOLET","expiryDate":"2038-03-23"},{"type":"Formulation","number":"9168238","applicant":"FRESENIUS KABI USA LLC","territory":"US","tradeName":"LEVOTHYROXINE SODIUM","expiryDate":"2032-08-29"},{"type":"Formulation","number":"10406108","applicant":"GENUS LIFE SCIENCES INC","territory":"US","tradeName":"LEVOLET","expiryDate":"2038-03-23"},{"type":"Formulation","number":"9168239","applicant":"FRESENIUS KABI USA LLC","territory":"US","tradeName":"LEVOTHYROXINE SODIUM","expiryDate":"2032-08-29"},{"type":"Formulation","number":"11096913","applicant":"IBSA INSTITUT BIOCHIMIQUE SA","territory":"US","tradeName":"TIROSINT-SOL","expiryDate":"2037-02-28"},{"type":"Formulation","number":"11154498","applicant":"HIKMA PHARMACEUTICALS USA INC","territory":"US","tradeName":"LEVOTHYROXINE SODIUM","expiryDate":"2036-07-20"},{"type":"Formulation","number":"9345772","applicant":"MYLAN PHARMACEUTICALS INC","territory":"US","tradeName":"ERMEZA","expiryDate":"2035-02-27"},{"type":"Formulation","number":"10537538","applicant":"IBSA INSTITUT BIOCHIMIQUE SA","territory":"US","tradeName":"TIROSINT-SOL","expiryDate":"2037-02-28"},{"type":"Formulation","number":"9050307","applicant":"JEROME STEVENS PHARMACEUTICALS INC","territory":"US","tradeName":"THYQUIDITY","expiryDate":"2031-08-06"},{"type":"Formulation","number":"9006289","applicant":"FRESENIUS KABI USA LLC","territory":"US","tradeName":"LEVOTHYROXINE SODIUM","expiryDate":"2032-10-03"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$4.0753/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,487","description":"LEVOTHYROXINE 100 MCG CAPSULE","retrievedDate":"2026-04-07"}],"_fixedAt":"2026-03-30T11:29:38.341150","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Levothyroxine Sodium","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:36:06.588981+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:36:06.588904+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Levothyroxine Sodium","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:36:13.989826+00:00"},"mechanism":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:33:33.319759+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:36:11.913636+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:36:05.498352+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T08:33:33.319780+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Levothyroxine Sodium","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:36:12.426483+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:36:03.552594+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as th","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:36:03.552630+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:36:14.872119+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Thyroid hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:13.989757+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103741/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:13.641158+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA212399","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:36:03.552635+00:00"}},"offLabel":[],"timeline":[{"date":"20010525","type":"positive","milestone":"FDA approval — KING PHARMS","regulator":"FDA","description":""}],"_dailymed":{"setId":"008de8fd-150f-4022-8ccb-c8bfa94875c7","title":"LEVOTHYROXINE SODIUM TABLET [A-S MEDICATION SOLUTIONS]"},"aiSummary":"Levothyroxine sodium (Levoxyl) is a synthetic L-thyroxine (T4) replacement therapy indicated for hypothyroidism and TSH suppression in thyroid cancer management. The drug has a long half-life of 6-7 days, high protein binding (99.96%), and absorption of 40-80% from the gastrointestinal tract, with relative bioavailability of approximately 93% compared to solution formulations. Key risks include uncorrected adrenal insufficiency as an absolute contraindication, and numerous drug interactions affecting absorption through binding or pH changes, requiring careful timing of administration and TSH monitoring. Levothyroxine remains the standard thyroid hormone replacement therapy with well-established efficacy when appropriately dosed and monitored.","ecosystem":[],"mechanism":{"target":"Thyroid receptor proteins attached to DNA","novelty":"Me-too","modality":"L-thyroxine (T4) hormone","drugClass":"Thyroid hormone replacement","explanation":"Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.","oneSentence":"Levothyroxine binds thyroid receptors in cell nuclei to activate gene transcription and protein synthesis.","technicalDetail":"Levothyroxine acts as a ligand for thyroid hormone receptors (TRα and TRβ), which are ligand-activated transcription factors. Upon T4/T3 binding, these receptors dissociate from corepressor complexes and recruit coactivator proteins, enabling chromatin remodeling and transcriptional activation of thyroid hormone-responsive genes. The deiodinase enzymes (D1, D2, D3) regulate T4-to-T3 conversion and T3 catabolism, providing tissue-specific hormone bioavailability."},"_scrapedAt":"2026-03-27T23:28:02.647Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Levothyroxine","title":"Levothyroxine","extract":"Levothyroxine, also known as L-thyroxine, is a synthetic form of the thyroid hormone thyroxine (T4). It is used to treat thyroid hormone deficiency (hypothyroidism), including a severe form known as myxedema coma. It may also be used to treat and prevent certain types of thyroid tumors. It is not indicated for weight loss. Levothyroxine is taken orally (by mouth) or given by intravenous injection. Levothyroxine has a half-life of 7.5 days when taken daily, so about six weeks is required for it to reach a steady level in the blood."},"commercial":{"launchDate":"2001","annualCostUS":"$50-200/yr for generics","currentRevenue":"Generic — no single company revenue","peakSalesEstimate":"Generic — no single company revenue"},"references":[],"_validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:33:36.407990+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"name":"Synthroid","company":"AbbVie","advantage":"Most prescribed levothyroxine brand; consistent bioavailability and market dominance"},{"name":"Tirosint","company":"IBSA","advantage":"Liquid gel capsule formulation with superior absorption; fewer drug interactions"},{"name":"Armour Thyroid","company":"Allergan","advantage":"Desiccated thyroid extract containing T3 and T4; preferred by patients seeking natural alternative"},{"name":"Cytomel","company":"King Pharmaceuticals","advantage":"Liothyronine sodium (T3 only); used as adjunct therapy for patients not responding to T4 monotherapy"},{"name":"Nature-Throid","company":"RLC Labs","advantage":"Natural desiccated thyroid alternative; appeals to patients preferring non-synthetic options"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"},{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Primary hypothyroidism - replacement therapy","regulator":"FDA"},{"name":"Secondary hypothyroidism - replacement therapy","regulator":"FDA"},{"name":"Tertiary hypothyroidism - replacement therapy","regulator":"FDA"},{"name":"Congenital hypothyroidism - replacement therapy","regulator":"FDA"},{"name":"Acquired hypothyroidism - replacement therapy","regulator":"FDA"},{"name":"TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to surgery","regulator":"FDA"},{"name":"TSH suppression in thyrotropin-dependent well-differentiated thyroid cancer - adjunct to radioiodine therapy","regulator":"FDA"},{"name":"Hypothyroidism in adult patients","regulator":"FDA"},{"name":"Hypothyroidism in pediatric patients","regulator":"FDA"},{"name":"Hypothyroidism in neonates","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["generics(17)","patents(3)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06731764","phase":"PHASE2, PHASE3","title":"Novel Approaches to the Treatment of Hypothyroidism","status":"RECRUITING","sponsor":"UConn Health","startDate":"2024-12-10","conditions":"Hypothyroidism","enrollment":90},{"nctId":"NCT06724224","phase":"","title":"Comparison of Levothyroxine Formulations in the Treatment of Congenital Hypothyroidism","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2024-04-08","conditions":"Congenital Hypothyroidism","enrollment":120},{"nctId":"NCT07424183","phase":"PHASE2","title":"T4/T3 Therapy in Hypothyroidism","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-03","conditions":"Hypothyroidism Primary","enrollment":60},{"nctId":"NCT07421869","phase":"NA","title":"SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2024-06-12","conditions":"Hypothyroidism","enrollment":107},{"nctId":"NCT05526144","phase":"PHASE2","title":"Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-04-01","conditions":"Nonalcoholic Steatohepatitis, Liver Fibrosis","enrollment":128},{"nctId":"NCT06073665","phase":"PHASE4","title":"Dosing of LT4 in Older Individuals","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-01-31","conditions":"Hypothyroidism","enrollment":228},{"nctId":"NCT05712421","phase":"PHASE2","title":"A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism","status":"COMPLETED","sponsor":"Neuvosyn Laboratories, LLC","startDate":"2023-02-28","conditions":"Hypothyroidism","enrollment":303},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT06647602","phase":"","title":"Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2026-09-01","conditions":"Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine","enrollment":40},{"nctId":"NCT07393165","phase":"NA","title":"Levothyroxine Treatment on Cardiac Function in Children With Subclinical Hypothyroidism","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-05-24","conditions":"Levothyroxine, Cardiac Function, Children","enrollment":40},{"nctId":"NCT06790589","phase":"PHASE2","title":"COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2026-12","conditions":"Advanced Differentiated Thyroid Gland Carcinoma","enrollment":70},{"nctId":"NCT07380854","phase":"NA","title":"Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-02-27","conditions":"Subclinical Hypothyroidism","enrollment":338},{"nctId":"NCT01391962","phase":"PHASE2","title":"Sunitinib or Cediranib for Alveolar Soft Part Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-18","conditions":"Sarcoma, Alveolar Soft Part","enrollment":34},{"nctId":"NCT07257250","phase":"","title":"Levothyroxine Treatment and IVF Outcomes in Women With Subclinical Hypothyroidism: A Target Trial Emulation","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2019-01-01","conditions":"Subclinical Hypothyroidism, Infertility, Assisted Reproductive Technology","enrollment":900},{"nctId":"NCT07332273","phase":"PHASE3","title":"Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2025-11-05","conditions":"Obesity","enrollment":286},{"nctId":"NCT07323706","phase":"NA","title":"Ayurvedic Diet in Myxedema","status":"RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-10-01","conditions":"Hypothyroidism Primary","enrollment":88},{"nctId":"NCT06345339","phase":"PHASE2, PHASE3","title":"A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-04-26","conditions":"Hypothyroidism","enrollment":2800},{"nctId":"NCT07239674","phase":"PHASE3","title":"Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-30","conditions":"Intermediate-to-High Risk Differentiated Thyroid Cancer","enrollment":646},{"nctId":"NCT05228184","phase":"PHASE4","title":"Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)","status":"TERMINATED","sponsor":"IBSA Institut Biochimique SA","startDate":"2022-01-21","conditions":"Congenital Hypothyroidism","enrollment":34},{"nctId":"NCT04115514","phase":"PHASE2","title":"Treatment of ARDS With Instilled T3","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2020-03-30","conditions":"ARDS, Human, Lung, Wet, Thyroid","enrollment":68},{"nctId":"NCT07205042","phase":"NA","title":"Walking for Hypothyroidism Trial (WHT)","status":"NOT_YET_RECRUITING","sponsor":"University of Karachi","startDate":"2025-11-01","conditions":"Hypothyroidism","enrollment":120},{"nctId":"NCT06083636","phase":"","title":"Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-07-26","conditions":"Hypothyroidism","enrollment":500},{"nctId":"NCT06652113","phase":"NA","title":"Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-11-15","conditions":"Recurrent Pregnancy Loss, Euthyroid With Thyroid Antibodies","enrollment":796},{"nctId":"NCT06455371","phase":"NA","title":"Patient-centered Dosage of Levothyroxine","status":"RECRUITING","sponsor":"University Hospital of North Norway","startDate":"2024-12-20","conditions":"Hypothyroidism, Thyroid Cancer, Thyroid","enrollment":240},{"nctId":"NCT03977207","phase":"NA","title":"A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-07-20","conditions":"Thyroid; Functional Disturbance, Hypothyroidism, Hemodialysis","enrollment":336},{"nctId":"NCT06864351","phase":"NA","title":"Prospective Evaluation of OptiThyDose","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2025-08-28","conditions":"Thyroid Diseases, Congenital Hypothyroidism, Graves Disease","enrollment":150},{"nctId":"NCT06041204","phase":"NA","title":"Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism","status":"RECRUITING","sponsor":"Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy","startDate":"2021-05-06","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Subclinical Hypothyroidism, Female Infertility","enrollment":200},{"nctId":"NCT07133295","phase":"","title":"Long-Term Efficacy and Safety of Once-Weekly Levothyroxine Regimen in Hypothyroid Patients","status":"COMPLETED","sponsor":"Sohag University","startDate":"2021-03-23","conditions":"Hypothyroidism","enrollment":160},{"nctId":"NCT06660823","phase":"PHASE3","title":"Role of Levothyroxine Supplementation in Delayed Recovery Following Cardiac Surgery","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-11-30","conditions":"Cardiac Surgery Intensive Care Treatment, Delayed Recovery From Anaesthesia, Euthyroid Sick Syndrome","enrollment":70},{"nctId":"NCT05823012","phase":"PHASE2","title":"Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism","status":"COMPLETED","sponsor":"Xeris Pharmaceuticals","startDate":"2023-05-15","conditions":"Hypothyroidism","enrollment":46},{"nctId":"NCT07011953","phase":"EARLY_PHASE1","title":"A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-07-01","conditions":"Schizophrenia, Avolition","enrollment":90},{"nctId":"NCT06999278","phase":"PHASE3","title":"LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-06-01","conditions":"Abortion, Habitual","enrollment":200},{"nctId":"NCT06428097","phase":"PHASE1","title":"Levothyroxine Supplementation for Heart Transplant Recipients","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-03-29","conditions":"Heart Transplant Failure, Heart Transplant Infection","enrollment":97},{"nctId":"NCT06867913","phase":"NA","title":"A Study of Selenomethionine and Myo-inositol(SOLOWAYS_TM) in Patients With Autoimmune Thyroiditis Carrying the DIO2 Thr92Ala Polymorphism","status":"COMPLETED","sponsor":"S.LAB (SOLOWAYS)","startDate":"2024-05-15","conditions":"Autoimmune Thyroiditis","enrollment":40},{"nctId":"NCT06924242","phase":"","title":"Thyroid Cancer in Surgical Treated Multinodular Goiter","status":"COMPLETED","sponsor":"University of Foggia","startDate":"2018-01-01","conditions":"Goiter, Nodular, Total Thyroidectomy, Thyroid Cancer","enrollment":223},{"nctId":"NCT06649318","phase":"","title":"Effect of Brain GABA Metabolite Amount to Propofol Utilisation Under TIVA in Hypothyroid Patient","status":"COMPLETED","sponsor":"Duzce University","startDate":"2023-06-23","conditions":"Hypothyroidism, Anesthesia, General, Propofol Dosage","enrollment":80},{"nctId":"NCT06276205","phase":"PHASE3","title":"Vitamin D & Levothyroxine Combination Versus Levothyroxine on Lipid Profile in Hypothyroidism","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2024-03-01","conditions":"Hypothyroidism Primary, Lipid Disorder, Dyslipidemias","enrollment":62},{"nctId":"NCT03880578","phase":"","title":"Quality of Life After Interventional Thyroid Treatment","status":"COMPLETED","sponsor":"Klinikum Lüdenscheid","startDate":"2019-04-01","conditions":"Thyroid; Deficiency, Quality of Life","enrollment":101},{"nctId":"NCT06653907","phase":"PHASE4","title":"Levothyroxine Intervention in Pregnant Women with TSH （2.5 MIU/L-upper Limit of Reference Range） and Negative Thyroid Peroxidase Antibody","status":"NOT_YET_RECRUITING","sponsor":"Yang ZHANG","startDate":"2024-10-25","conditions":"Thyroid Abnormalities, Pregnant Woman, Pregnancy Outcomes","enrollment":400},{"nctId":"NCT06641440","phase":"PHASE4","title":"Treatment With Prednisone of Women With RPL or RIF Positive to Antithyroid Antibodies and Embryotoxicity Test","status":"COMPLETED","sponsor":"Centre for Endocrinology and Reproductive Medicine, Italy","startDate":"2018-01-01","conditions":"Recurrent Pregnancy Loss, Not Pregnant, Recurrent Implantation Failure","enrollment":42},{"nctId":"NCT06625814","phase":"PHASE1","title":"A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-08","conditions":"Healthy","enrollment":28},{"nctId":"NCT05412979","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism","status":"COMPLETED","sponsor":"Sention Therapeutics, LLC","startDate":"2022-04-29","conditions":"Hypothyroidism","enrollment":490},{"nctId":"NCT05276856","phase":"","title":"Recovery Rate in Secondary Hypothyroidism","status":"RECRUITING","sponsor":"Nova Scotia Health Authority","startDate":"2022-04-04","conditions":"Secondary Hypothyroidism","enrollment":90},{"nctId":"NCT06547242","phase":"PHASE1","title":"Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration","status":"COMPLETED","sponsor":"Berlin-Chemie AG Menarini Group","startDate":"2021-10-22","conditions":"Healthy","enrollment":132},{"nctId":"NCT06373523","phase":"EARLY_PHASE1","title":"MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-09-01","conditions":"Hepatic Steato-Fibrosis, Non-Alcoholic Fatty Liver Disease","enrollment":60},{"nctId":"NCT06527859","phase":"","title":"Correlation Between Levothyroxine and Blood Th17/Treg in Pregnant Women With Normal-high TSH and Positive TPOAb","status":"TERMINATED","sponsor":"Third Affiliated Hospital of Zhengzhou University","startDate":"2022-04-06","conditions":"Pregnancy Related, Thyroid Stimulating; Hormone, C","enrollment":64},{"nctId":"NCT04782856","phase":"PHASE2","title":"Energy Metabolism in Thyroidectomized Patients","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2020-10-28","conditions":"Thyroid Goiter, Hypothyroidism, Thyroid Cancer","enrollment":13},{"nctId":"NCT04124705","phase":"PHASE2","title":"A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-10-11","conditions":"Hypothyroidism, Thyroid Disease, Euthyroid","enrollment":284},{"nctId":"NCT06408909","phase":"NA","title":"Pharmacist Role in Thyroid Disorders","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2022-03-15","conditions":"Hypothyroidism, Hyperthyroidism, Thyroid Diseases","enrollment":44},{"nctId":"NCT00648557","phase":"PHASE1","title":"Fasting Study of Levothyroxine Sodium Tablets 200 mg to Synthroid Tablets 200 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-01","conditions":"Healthy","enrollment":32},{"nctId":"NCT00648700","phase":"PHASE1","title":"Fasting Study of Levothyroxine Sodium Tablets 300 μg to Levothroid® Tablets 300 μg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-08","conditions":"Healthy","enrollment":32},{"nctId":"NCT00648882","phase":"PHASE1","title":"Fasting Study of Levothyroxine Sodium Tablets 300 mcg to Synthroid® Tablets 300 mcg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2007-03","conditions":"Healthy","enrollment":33},{"nctId":"NCT00647855","phase":"PHASE1","title":"Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-05","conditions":"Healthy","enrollment":30},{"nctId":"NCT06353555","phase":"NA","title":"Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-10-11","conditions":"Intracerebral Hemorrhage, Low T3 Syndrome, Neurocritical Care","enrollment":100},{"nctId":"NCT05733078","phase":"PHASE2","title":"Effect of Vitamin C Supplementation in Patients With Primary Hypothyroidism","status":"UNKNOWN","sponsor":"Dr Adnan Agha","startDate":"2023-11-01","conditions":"Hypothyroidism, Primary Hypothyroidism, Vitamin C Deficiency","enrollment":40},{"nctId":"NCT04415658","phase":"PHASE3","title":"Intravenous Thyroxine for Heart-Eligible Organ Donors","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-12-01","conditions":"Brain Death, Heart Failure","enrollment":838},{"nctId":"NCT05461820","phase":"PHASE4","title":"Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-05-01","conditions":"Graves Disease, Relapse, Treatment","enrollment":240},{"nctId":"NCT05316922","phase":"PHASE3","title":"TSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2021-12-13","conditions":"Hypothyroidism; Irradiation","enrollment":68},{"nctId":"NCT06135948","phase":"PHASE4","title":"Impact of Increasing Levothyroxine Dose in Ramadan for UAE Patients With Hypothyroidism","status":"COMPLETED","sponsor":"Emirates Health Services (EHS)","startDate":"2022-03-15","conditions":"L-thyroxine","enrollment":103},{"nctId":"NCT04288115","phase":"PHASE4","title":"Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-03-24","conditions":"Subclinical Hypothyroidism","enrollment":52},{"nctId":"NCT06036576","phase":"PHASE3","title":"Thyroxine Therapy for Recurrent Pregnancy Loss in Hypothyroid Women","status":"COMPLETED","sponsor":"Al-Kindy College of Medicine","startDate":"2022-03-01","conditions":"Recurrent Early Pregnancy Loss, Thyroid Diseases","enrollment":77},{"nctId":"NCT04747275","phase":"PHASE4","title":"Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients","status":"TERMINATED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2021-01-18","conditions":"Hypothyroidism, Trisomy 21","enrollment":6},{"nctId":"NCT02567877","phase":"","title":"Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2016-11","conditions":"Postsurgical Hypothyroidism, Hypothyroidism","enrollment":12},{"nctId":"NCT04354896","phase":"PHASE4","title":"The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2014-05","conditions":"Subclinical Hypothyroidism, Sarcopenia","enrollment":322},{"nctId":"NCT05216913","phase":"","title":"Optimising Cardiovascular Health in Endometrial Cancer Survivors","status":"UNKNOWN","sponsor":"University of Manchester","startDate":"2022-02-09","conditions":"Endometrial Cancer, Cardiovascular Diseases","enrollment":80},{"nctId":"NCT03053115","phase":"PHASE2, PHASE3","title":"Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients","status":"COMPLETED","sponsor":"Azienda USL Modena","startDate":"2017-03-14","conditions":"Hypothyroidism","enrollment":160},{"nctId":"NCT05821881","phase":"","title":"REduction of LEvothyroxine in Adults; a SElf Controlled Study","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2020-02-13","conditions":"Hypothyroidism","enrollment":513},{"nctId":"NCT00788307","phase":"PHASE1","title":"Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2008-11-03","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT04878614","phase":"PHASE4","title":"Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2021-05-05","conditions":"Hypothyroidism","enrollment":3},{"nctId":"NCT05804149","phase":"PHASE2","title":"Effect of Acupuncture and Low Caloric Diet on Primary Hypothyroidism and Irregular Menstruation in Infertile Women","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-08-30","conditions":"Primary Hypothyroidism, Acupuncture, Irregular Menstruation","enrollment":60},{"nctId":"NCT05803967","phase":"NA","title":"Baduanjin Exercising Effects on Sub-clinical Hypothyroidism and Cognitive Problems","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-12-18","conditions":"Subclinical hypothyroïdism, Cognitive Impairment","enrollment":40},{"nctId":"NCT04868045","phase":"PHASE1","title":"Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer","status":"WITHDRAWN","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-27","conditions":"Thyroid Cancer","enrollment":""},{"nctId":"NCT05174000","phase":"PHASE1","title":"BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-01-10","conditions":"Healthy","enrollment":56},{"nctId":"NCT02548715","phase":"PHASE2, PHASE3","title":"Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2015-07","conditions":"Hypothyroidism, Neoplasms, Postoperative Complications","enrollment":""},{"nctId":"NCT03390530","phase":"PHASE3","title":"Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage","status":"WITHDRAWN","sponsor":"Albert Einstein College of Medicine","startDate":"2022-01-18","conditions":"Intraventricular Hemorrhage of Prematurity","enrollment":""},{"nctId":"NCT03787303","phase":"PHASE2","title":"Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma","status":"TERMINATED","sponsor":"Aultman Health Foundation","startDate":"2019-03-01","conditions":"Metastatic Breast Cancer, Thyroid Dysfunction","enrollment":7},{"nctId":"NCT05371262","phase":"PHASE4","title":"Influence of Initial Levothyroxine Dose on Neurodevelopmental and Growth Outcomes in Congenital Hypothyroidism","status":"COMPLETED","sponsor":"Federico II University","startDate":"2011-05","conditions":"Congenital Hypothyroidism","enrollment":72},{"nctId":"NCT05240911","phase":"NA","title":"Individual Dosing of Levothyroxine After Thyroidectomy","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-06-01","conditions":"Thyroid Neoplasms, Hypothyroidism, Surgery","enrollment":202},{"nctId":"NCT03094416","phase":"PHASE4","title":"Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2018-07-30","conditions":"Hypothyroidism;Postablative","enrollment":66},{"nctId":"NCT03342001","phase":"PHASE4","title":"Hypothyroidism Treated With Calcitonin","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-06-18","conditions":"Hypothyroidism","enrollment":11},{"nctId":"NCT04988802","phase":"NA","title":"The Effect of Dietary Supplements for Pregnant Women on Levothyroxine Absorption","status":"UNKNOWN","sponsor":"University Hospital Dubrava","startDate":"2021-10-20","conditions":"Hypothyroidism Primary","enrollment":37},{"nctId":"NCT03391154","phase":"PHASE3","title":"Efficacy of Low Dose Levothyroxine During Pregnancy","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-05-01","conditions":"Euthyroid Females","enrollment":180},{"nctId":"NCT02577367","phase":"PHASE4","title":"Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding","status":"WITHDRAWN","sponsor":"Jocelyne Karam","startDate":"2015-10-01","conditions":"Hypothyroidism","enrollment":""},{"nctId":"NCT04953195","phase":"PHASE4","title":"Thyroid Replacement Therapy in Patients With Subclinical Hypothyroidism","status":"UNKNOWN","sponsor":"Beijing Chao Yang Hospital","startDate":"2019-01-01","conditions":"Subclinical Hypothyroidisms","enrollment":30},{"nctId":"NCT03191188","phase":"NA","title":"A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients","status":"UNKNOWN","sponsor":"University of California, Irvine","startDate":"2017-07-01","conditions":"Thyroid Disease, Kidney Diseases, Chronic","enrollment":96},{"nctId":"NCT04880798","phase":"NA","title":"Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-05-06","conditions":"Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT04600349","phase":"NA","title":"Identity Oriented Psychotrauma Therapy on Hashimoto in Adults","status":"COMPLETED","sponsor":"University of Bucharest","startDate":"2020-02-01","conditions":"Autoimmune Thyroiditis","enrollment":70},{"nctId":"NCT04472988","phase":"NA","title":"Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults","status":"COMPLETED","sponsor":"University of Bucharest","startDate":"2020-01-01","conditions":"Hashimoto","enrollment":91},{"nctId":"NCT03098433","phase":"PHASE1, PHASE2","title":"Effects of Liothyronine on Energy Expenditure and Cardiovascular Function","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2017-10-20","conditions":"Healthy","enrollment":22},{"nctId":"NCT03627611","phase":"PHASE2","title":"Identification of Non-responders to Levothyroxine Therapy","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2018-08-14","conditions":"Hypothyroidism, Biomarkers, Endocrine System Diseases","enrollment":69},{"nctId":"NCT02399475","phase":"NA","title":"Mechanistic Study of Subclinical Hypothyroidism In the Elderly","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2015-01-01","conditions":"Subclinical Hypothyroidism","enrollment":14},{"nctId":"NCT04712760","phase":"","title":"Congenital Hypothyroidism in Children With Eutopic Gland or Thyroid Hemiagenesis: Predictive Factors for Transient vs Permanent Hypothyroidism.","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2021-02-22","conditions":"Congenital Hypothyroidism","enrollment":60},{"nctId":"NCT01707056","phase":"NA","title":"The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma","status":"WITHDRAWN","sponsor":"Medstar Health Research Institute","startDate":"2012-09","conditions":"Thyroid Carcinoma, Hypothyroidism","enrollment":""},{"nctId":"NCT03979274","phase":"PHASE1","title":"A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2019-12-06","conditions":"Healthy","enrollment":44},{"nctId":"NCT04332770","phase":"","title":"Biosignals by Wearable Devices in Hypothyroidism","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2019-06-14","conditions":"Hypothyroidism","enrollment":45},{"nctId":"NCT02946918","phase":"PHASE4","title":"Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-02-01","conditions":"Thyroid Cancer, Postsurgical Hypothyroidism","enrollment":14},{"nctId":"NCT04648722","phase":"","title":"Higher Levothyroxine Requirements After Right-side Hemithyroidectomy","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-05-05","conditions":"Hemithyroidectomy, Hypothyroidism","enrollment":459},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT01145040","phase":"","title":"NOMOTHETICOS: Nonlinear Modelling of Thyroid Hormones' Effect on Thyrotropin Incretion in Confirmed Open-loop Situation","status":"UNKNOWN","sponsor":"Ruhr University of Bochum","startDate":"2010-06-01","conditions":"Hypothyroidism, Hyperthyroidism","enrollment":138},{"nctId":"NCT04573907","phase":"PHASE4","title":"Bioequivalence Study of Levothyroxine Sodium Tablets 100 mcg","status":"COMPLETED","sponsor":"Tecnoquimicas","startDate":"2019-06-01","conditions":"Healthy","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":1323,"reaction":"DRUG INEFFECTIVE"},{"count":1280,"reaction":"FATIGUE"},{"count":1194,"reaction":"NAUSEA"},{"count":987,"reaction":"HEADACHE"},{"count":933,"reaction":"DIZZINESS"},{"count":857,"reaction":"DIARRHOEA"},{"count":800,"reaction":"DYSPNOEA"},{"count":793,"reaction":"PAIN"},{"count":736,"reaction":"ASTHENIA"},{"count":679,"reaction":"MALAISE"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.medfinder.com/blog/levoxyl-shortage-update-what-patients-need-to-know-in-2026","date":"2026-04-07","type":"news","title":"Levoxyl Shortage Update: What Patients Need to Know in 2026","source":"www.medfinder.com"},{"url":"https://media.milliman.com/v1/media/edge/images/millimaninc5660-milliman6442-prod27d5-0001/media/Milliman/PDFs/2026-Articles/1-27-26_2025-Commercial-Drug-Trend-Study.pdf","date":"2026-04-07","type":"news","title":"[PDF] Commercial drug trends Looking to 2026 and onward - Milliman","source":"media.milliman.com"},{"url":"https://www.intelmarketresearch.com/thyroxine-market-23986","date":"2026-04-07","type":"news","title":"Thyroxine T4 Market Outlook 2026-2032 - Intel Market Research","source":"www.intelmarketresearch.com"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021301s038lbl.pdf","date":"2026-04-07","type":"news","title":"[PDF] This label may not be the latest approved by FDA. For current ...","source":"www.accessdata.fda.gov"},{"url":"https://labeling.pfizer.com/showlabeling.aspx?id=688","date":"2026-04-07","type":"news","title":"highlights of prescribing information - Pfizer","source":"labeling.pfizer.com"}],"manufacturing":[],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"unii":"9J765S329G","rxcui":"40144","splId":"f059a576-bb4b-441d-917e-4338bc3df403","chemblId":"CHEMBL2103741","pubchemSID":"50054748"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"tmax":"","halfLife":"6 to 7 days (3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism)","clearance":"Slowly eliminated; urinary excretion of T4 decreases with age","excretion":"Primarily eliminated by kidneys; approximately 20% of T4 eliminated in stool; conjugated hormone undergoes enterohepatic recirculation","metabolism":"Major pathway is sequential deiodination; approximately 80% of daily T4 dose is deiodinated to yield equal amounts of T3 and reverse T3 (rT3); liver is major site of degradation; also metabolized via conjugation with glucuronides and sulfates","proteinBinding":"99.96%","bioavailability":"Approximately 93% relative bioavailability compared to oral levothyroxine sodium solution; oral absorption ranges from 40% to 80%","volumeOfDistribution":""},"publicationCount":356,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"commercialAnalysis":{"text":"Levoxyl, a levothyroxine sodium medication developed by Pfizer Inc., is a widely used treatment for hypothyroidism. According to Milliman's commercial drug trends report, Levoxyl is a top-selling medication in the thyroid hormone replacement therapy market [1, 2026]. However, the market is expected to experience a shortage due to supply chain disruptions, as reported by MedFinder in February 2026 [2]. This shortage may impact revenue, which was not disclosed in the provided sources.\n\nThe competitive landscape for Levoxyl is relatively stable, with few direct competitors in the levothyroxine sodium market. However, the market is expected to experience increased competition from biosimilars and generic versions of levothyroxine sodium, which may erode market share [3]. Additionally, the patent for Levoxyl is set to expire, allowing generic versions to enter the market and further challenge Pfizer's market position.\n\nKey upcoming catalysts for the Levoxyl market include the potential for label expansions, which could increase the medication's indications and patient base. However, the market is also expected to experience increased competition from pipeline competitors, such as new thyroid hormone replacement therapies [4]. According to Intel Market Research, the global Thyroxine (T4) market is projected to grow from USD 174 million in 2025 to USD 214 million by 2032, driven by increasing prevalence of thyroid disorders and rising demand for hormone replacement therapies [5].\n\nOverall, the market outlook for Levoxyl is uncertain due to the impending shortage and increased competition from biosimilars and generic versions. However, the potential for label expansions and the growing demand for hormone replacement therapies may provide opportunities for growth.\n\nReferences:\n[1] Milliman, 2026\n[2] MedFinder, February 2026\n[3] Milliman, 2026\n[4] Intel Market Research, 2025\n[5] Intel Market Research, 2025","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.medfinder.com/blog/levoxyl-shortage-update-what-patients-need-to-know-in-2026","date":"","title":"Levoxyl Shortage Update: What Patients Need to Know in 2026","source":"www.medfinder.com"},{"url":"https://media.milliman.com/v1/media/edge/images/millimaninc5660-milliman6442-prod27d5-0001/media/Milliman/PDFs/2026-Articles/1-27-26_2025-Commercial-Drug-Trend-Study.pdf","date":"","title":"[PDF] Commercial drug trends Looking to 2026 and onward - Milliman","source":"media.milliman.com"},{"url":"https://www.intelmarketresearch.com/thyroxine-market-23986","date":"","title":"Thyroxine T4 Market Outlook 2026-2032 - Intel Market Research","source":"www.intelmarketresearch.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"companionDiagnostics":[{"biomarker":"TSH (Thyroid-Stimulating Hormone)","requirement":"recommended","diagnosticId":"cdx-0","diagnosticName":"FDA-approved test"},{"biomarker":"Free thyroxine (FT4)","requirement":"recommended","diagnosticId":"cdx-1","diagnosticName":"FDA-approved test"}],"genericManufacturers":17,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Amneal","Ani Pharms","Ascent Pharms Inc","Aurobindo Pharma","Dr Reddys","Lupin","Macleods Pharms Ltd","Maia Pharms Inc","Merck Kgaa","Mylan","Onesource Specialty","Ph Health","Piramal Critical","Watson Labs Teva","Xiromed","Zydus Pharms"],"phase":"marketed","status":"approved","brandName":"Levoxyl","genericName":"Levothyroxine Sodium","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"2001","enrichmentLevel":5,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-05-25T00:00:00.000Z","mah":"KING PHARMS","brand_name_local":null,"application_number":"NDA021301"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-03-26T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":"NDA021292"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-12-21T00:00:00.000Z","mah":"MAIA PHARMS INC","brand_name_local":null,"application_number":"ANDA208749"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-04-29T00:00:00.000Z","mah":"MYLAN","brand_name_local":null,"application_number":"NDA215809"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-03-24T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":null,"application_number":"ANDA217066"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"1487.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1487.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1487.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1487.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"1487.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":14,"withResults":3},"validation":{"fieldsValidated":7,"lastValidatedAt":"2026-04-20T08:33:36.407990+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}